デフォルト表紙
市場調査レポート
商品コード
1630595

抗真菌剤の市場規模、シェア、成長分析、薬剤タイプ別、治療適応症別、タイプ別、投与経路別、流通チャネル別、地域別 - 産業予測、2025~2032年

Antifungal Agents Market Size, Share, Growth Analysis, By Drug Type, By Therapeutic Indication, By Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032


出版日
発行
SkyQuest
ページ情報
英文 219 Pages
納期
3~5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.95円
抗真菌剤の市場規模、シェア、成長分析、薬剤タイプ別、治療適応症別、タイプ別、投与経路別、流通チャネル別、地域別 - 産業予測、2025~2032年
出版日: 2025年01月09日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗真菌剤の世界市場規模は2023年に149億米ドルと評価され、2024年の155億米ドルから2032年には212億1,000万米ドルに成長し、予測期間(2025~2032年)のCAGRは4.0%で成長する見通しです。

抗真菌剤市場は、真菌感染症の有病率の上昇と効果的な治療に対する需要の高まりにより、大幅な成長が見込まれています。抗真菌研究への旺盛な投資とともに、創薬・開発プロセスの大幅な進歩が市場ダイナミクスを高めると予想されます。未開発・発展途上地域の新興国市場は、医療提供者にとって有利なビジネスチャンスとなります。しかし、抗真菌剤耐性や使用可能な薬剤の範囲が限られているなどの課題が、長期的な市場拡大の制約となる可能性があります。全体として、需要の拡大、技術の進歩、調査への投資の組み合わせは、潜在的なハードルはあるにせよ、今後数年間の調査市場の見通しが明るいことを示唆しています。

目次

イントロダクション

  • 調査の目的
  • 調査範囲
  • 定義

調査手法

  • 情報調達
  • 二次データと一次データの方法
  • 市場規模予測
  • 市場の前提条件と制限

エグゼクティブサマリー

  • 世界市場の見通し
  • 供給と需要の動向分析
  • セグメント別機会分析

市場力学と見通し

  • 市場概要
  • 市場規模
  • 市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターの分析

主な市場の考察

  • 重要成功要因
  • 競合の程度
  • 主な投資機会
  • 市場エコシステム
  • 市場の魅力指数(2024年)
  • PESTEL分析
  • マクロ経済指標
  • バリューチェーン分析
  • 価格分析
  • 規制情勢
  • ケーススタディ
  • 技術の進歩
  • 貿易分析
  • 顧客と購買基準の分析
  • 原材料の分析

抗真菌剤市場規模:薬剤タイプ別

  • 市場概要
  • 全身性アゾールおよびポリエン
  • 局所用アゾールおよびポリエン
  • 全身性エキノカンジンおよび代謝拮抗薬
  • その他

抗真菌剤市場規模:治療適応症別

  • 市場概要
  • 皮膚糸状菌症
  • カンジダ症
  • アスペルギルス症
  • その他

抗真菌剤市場規模:タイプ別

  • 市場概要
  • 処方箋
  • 市販薬(OTC)

抗真菌剤市場規模:投与経路別

  • 市場概要
  • 経口
  • 局所
  • 非経口

抗真菌剤市場規模:流通チャネル別

  • 市場概要
  • 病院薬局
  • 小売薬局・ドラッグストア
  • オンライン薬局

抗真菌剤市場規模

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • イタリア
    • その他欧州地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • その他ラテンアメリカ地域
  • 中東・アフリカ
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ

競合情報

  • 上位5社の比較
  • 主要企業の市場ポジショニング(2024年)
  • 主な市場企業が採用した戦略
  • 市場の最近の動向
  • 企業の市場シェア分析(2024年)
  • 主要企業の企業プロファイル
    • 会社概要
    • 製品ポートフォリオ分析
    • セグメント別シェア分析
    • 収益の前年比比較(2022-2024)

主要企業プロファイル

  • Abbott(USA)
  • Bayer AG(Germany)
  • GSK plc(UK)
  • Merck & Co., Inc.(USA)
  • Cadila Pharmaceuticals(India)
  • Glenmark Pharmaceuticals(India)
  • SCYNEXIS, Inc.(USA)
  • Astellas Pharma Inc.(Japan)
  • Arcadia Consumer Healthcare(USA)
  • Novartis AG(Switzerland)
  • Pfizer Inc.(USA)
  • Leadiant Biosciences, Inc.(USA)
  • Sun Pharmaceutical Industries Ltd.(India)
  • Viatris Inc.(USA)
  • Sanofi(France)
  • Gilead Sciences, Inc.(USA)
  • Apotex Inc.(Canada)
  • Aurobindo Pharma Limited(India)
  • Cipla Inc.(India)
  • Dr. Reddy's Laboratories Ltd.(India)

結論と推奨事項

目次
Product Code: SQMIG35J2113

Global Antifungal Agents Market size was valued at USD 14.9 billion in 2023 and is poised to grow from USD 15.5 billion in 2024 to USD 21.21 billion by 2032, growing at a CAGR of 4.0% during the forecast period (2025-2032).

The antifungal agents market is poised for substantial growth, driven by the rising prevalence of fungal infections and an increasing demand for effective treatments. Significant advancements in drug discovery and development processes are expected to enhance market dynamics, alongside robust investments in antifungal research. Emerging markets in underdeveloped and developing regions present lucrative opportunities for providers. However, challenges such as antifungal resistance and the limited spectrum of available agents could pose constraints on long-term market expansion. Overall, the combination of growing demand, technological advancements, and investment in research suggests a positive outlook for the antifungal agents market in the coming years, despite the potential hurdles that may arise.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antifungal Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antifungal Agents Market Segmental Analysis

Global Antifungal Agents Market is segmented by Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Systemic Azoles & Polyenes, Topical Azoles & Polyenes, Systemic Echinocandins & Antimetabolics and Others. Based on Therapeutic Indication, the market is segmented into Dermatophytosis, Candidiasis, Aspergillosis and Others. Based on Type, the market is segmented into Prescription and Over the counter (OTC). Based on Route of Administration, the market is segmented into Oral, Topical and Parenteral. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies & Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antifungal Agents Market

The global antifungal agents market is primarily driven by the rising incidence of fungal infections, which can be attributed to the widespread antibiotic resistance and the increasing prevalence of chronic infectious diseases. As more patients succumb to fungal infections due to these factors, there is an anticipated surge in the demand for antifungal agents. This escalation highlights the critical need for effective treatments to combat these infections, further propelling the market's growth. With healthcare providers seeking reliable solutions, the antifungal agents market is poised for significant expansion in response to these pressing health challenges.

Restraints in the Global Antifungal Agents Market

The global antifungal agents market faces significant limitations due to the rising phenomenon of antifungal resistance. As fungal pathogens evolve and become increasingly resistant to commonly prescribed antifungal treatments, the effectiveness of these agents diminishes, leading to a concerning epidemic of resistance. This situation poses a serious threat to the market's growth potential, as many antifungal medications may become ineffective in treating infections, ultimately impacting clinical outcomes and increasing the burden on healthcare systems. If left unaddressed, this growing challenge could hinder innovation and development of new antifungal treatments, thereby stalling market expansion in the foreseeable future.

Market Trends of the Global Antifungal Agents Market

The Global Antifungal Agents market is witnessing a notable trend towards personalized medicine, with vendors increasingly partnering with biotech firms to create tailored treatments for diverse fungal infections. By leveraging advancements in personalized approaches, such as precision diagnostics and targeted therapies, antifungal agents can enhance efficacy and improve patient outcomes. This collaboration not only addresses the unique genetic and clinical profiles of patients but also offers lucrative revenue opportunities for companies willing to innovate. As awareness of personalized medicine grows, stakeholders in the antifungal sector are positioned to capitalize on this trend, driving market growth and elevating treatment standards globally.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Landscape
  • Case Studies
  • Technological Advancement
  • Trade Analysis
  • Customer & Buying Criteria Analysis
  • Raw Material Analysis

Global Antifungal Agents Market Size by Drug Type & CAGR (2025-2032)

  • Market Overview
  • Systemic Azoles & Polyenes
  • Topical Azoles & Polyenes
  • Systemic Echinocandins & Antimetabolics
  • Others

Global Antifungal Agents Market Size by Therapeutic Indication & CAGR (2025-2032)

  • Market Overview
  • Dermatophytosis
  • Candidiasis
  • Aspergillosis
  • Others

Global Antifungal Agents Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Prescription
  • Over the counter (OTC)

Global Antifungal Agents Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral
  • Topical
  • Parenteral

Global Antifungal Agents Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospitals Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

Global Antifungal Agents Market Size & CAGR (2025-2032)

  • North America (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
    • US
    • Canada
  • Europe (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Drug Type, Therapeutic Indication, Type, Route of Administration, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Abbott (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GSK plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cadila Pharmaceuticals (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Glenmark Pharmaceuticals (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SCYNEXIS, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arcadia Consumer Healthcare (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Leadiant Biosciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viatris Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Apotex Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aurobindo Pharma Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cipla Inc. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations